134 related articles for article (PubMed ID: 8695822)
1. Electroporation of synthetic oligodeoxynucleotides: a novel technique for ex vivo bone marrow purging.
Bergan R; Hakim F; Schwartz GN; Kyle E; Cepada R; Szabo JM; Fowler D; Gress R; Neckers L
Blood; 1996 Jul; 88(2):731-41. PubMed ID: 8695822
[TBL] [Abstract][Full Text] [Related]
2. Cationic lipids reduce time and dose of c-myc antisense oligodeoxynucleotides required to specifically inhibit Burkitt's lymphoma cell growth.
Williams SA; Chang L; Buzby JS; Suen Y; Cairo MS
Leukemia; 1996 Dec; 10(12):1980-9. PubMed ID: 8946941
[TBL] [Abstract][Full Text] [Related]
3. Effects of phosphodiester and phosphorothioate antisense oligodeoxynucleotides on cell lines which overexpress c-myc: implications for the treatment of Burkitt's lymphoma.
Williams SA; Gillan ER; Knoppel E; Buzby JS; Suen Y; Cairo MS
Ann Oncol; 1997; 8 Suppl 1():25-30. PubMed ID: 9187425
[TBL] [Abstract][Full Text] [Related]
4. Effects of BCR-ABL antisense oligonucleotides (AS-ODN) on human chronic myeloid leukemic cells: AS-ODN as effective purging agents.
Wu AG; Joshi SS; Chan WC; Iversen PL; Jackson JD; Kessinger A; Pirruccello SJ; Sanger WG; Sharp JG; Verbik DJ
Leuk Lymphoma; 1995 Dec; 20(1-2):67-76. PubMed ID: 8750625
[TBL] [Abstract][Full Text] [Related]
5. Bone marrow purging with antisense oligodeoxynucleotides.
Gewirtz AM
Prog Clin Biol Res; 1992; 377():215-24; discussion 225-6. PubMed ID: 1438418
[No Abstract] [Full Text] [Related]
6. Shiga-like toxin-1 receptor on human breast cancer, lymphoma, and myeloma and absence from CD34(+) hematopoietic stem cells: implications for ex vivo tumor purging and autologous stem cell transplantation.
LaCasse EC; Bray MR; Patterson B; Lim WM; Perampalam S; Radvanyi LG; Keating A; Stewart AK; Buckstein R; Sandhu JS; Miller N; Banerjee D; Singh D; Belch AR; Pilarski LM; Gariépy J
Blood; 1999 Oct; 94(8):2901-10. PubMed ID: 10515895
[TBL] [Abstract][Full Text] [Related]
7. Ex vivo bone marrow purging with oligonucleotides.
Bergan RC
Antisense Nucleic Acid Drug Dev; 1997 Jun; 7(3):251-5. PubMed ID: 9212920
[No Abstract] [Full Text] [Related]
8. Antisense oligodeoxynucleotide combination therapy of primary chronic myelogenous leukemia blast crisis in SCID mice.
Skorski T; Nieborowska-Skorska M; Wlodarski P; Zon G; Iozzo RV; Calabretta B
Blood; 1996 Aug; 88(3):1005-12. PubMed ID: 8704208
[TBL] [Abstract][Full Text] [Related]
9. Antitumor effect of c-myc antisense phosphorothioate oligodeoxynucleotides on human melanoma cells in vitro and and in mice.
Leonetti C; D'Agnano I; Lozupone F; Valentini A; Geiser T; Zon G; Calabretta B; Citro G C; Zupi G
J Natl Cancer Inst; 1996 Apr; 88(7):419-29. PubMed ID: 8618233
[TBL] [Abstract][Full Text] [Related]
10. Immunomagnetic purging of Ewing's sarcoma from blood and bone marrow: quantitation by real-time polymerase chain reaction.
Merino ME; Navid F; Christensen BL; Toretsky JA; Helman LJ; Cheung NK; Mackall CL
J Clin Oncol; 2001 Aug; 19(16):3649-59. PubMed ID: 11504746
[TBL] [Abstract][Full Text] [Related]
11. Normal and leukemic hematopoietic cells manifest differential sensitivity to inhibitory effects of c-myb antisense oligodeoxynucleotides: an in vitro study relevant to bone marrow purging.
Calabretta B; Sims RB; Valtieri M; Caracciolo D; Szczylik C; Venturelli D; Ratajczak M; Beran M; Gewirtz AM
Proc Natl Acad Sci U S A; 1991 Mar; 88(6):2351-5. PubMed ID: 2006173
[TBL] [Abstract][Full Text] [Related]
12. Autologous bone marrow transplantation in high-risk remission B-lineage acute lymphoblastic leukemia using a cocktail of three monoclonal antibodies (BA-1/CD24, BA-2/CD9, and BA-3/CD10) plus complement and 4-hydroperoxycyclophosphamide for ex vivo bone marrow purging.
Uckun FM; Kersey JH; Haake R; Weisdorf D; Ramsay NK
Blood; 1992 Feb; 79(4):1094-104. PubMed ID: 1531306
[TBL] [Abstract][Full Text] [Related]
13. Elimination of clonogenic Philadelphia-positive cells using BCR-ABL antisense oligodeoxynucleotides.
de Fabritiis P; Amadori S; Calabretta B; Mandelli F
Bone Marrow Transplant; 1993 Sep; 12(3):261-5. PubMed ID: 8241986
[TBL] [Abstract][Full Text] [Related]
14. Amifostine improves the antileukemic therapeutic index of mafosfamide: implications for bone marrow purging.
Douay L; Hu C; Giarratana MC; Bouchet S; Conlon J; Capizzi RL; Gorin NC
Blood; 1995 Oct; 86(7):2849-55. PubMed ID: 7670119
[TBL] [Abstract][Full Text] [Related]
15. Antiproliferative effect of c-myc antisense phosphorothioate oligodeoxynucleotides in malignant glioma cells.
Broaddus WC; Chen ZJ; Prabhu SS; Loudon WG; Gillies GT; Phillips LL; Fillmore H
Neurosurgery; 1997 Oct; 41(4):908-15. PubMed ID: 9316053
[TBL] [Abstract][Full Text] [Related]
16. Effect of Ethiofos on cytotoxicity of pharmacological purging protocols used for autologous marrow grafts in acute lymphoblastic leukemia.
Skala JP; Rogers PC; Chan KW; Rodriguez WC
Prog Clin Biol Res; 1992; 377():57-62. PubMed ID: 1332075
[No Abstract] [Full Text] [Related]
17. Efficacy of purging clonogenic leukemia cells using ether lipid and hyperthermia for autologous bone marrow transplantation.
Min WS; Park HM; Han CH; Park JW; Kim CC; Kim DJ
Prog Clin Biol Res; 1992; 377():87-95. PubMed ID: 1438449
[No Abstract] [Full Text] [Related]
18. The effect of a combined purging with mafosfamide and hyperthermia on murine haemopoietic stem cells and leukaemogenic cells.
Gidáli J; Fehér I
Bone Marrow Transplant; 1992 Dec; 10(6):479-83. PubMed ID: 1490197
[TBL] [Abstract][Full Text] [Related]
19. Effects of mafosfamide on the clonogenic cells in precursor B acute lymphoblastic leukemia: significance for ex vivo purging of bone marrow.
Kramer B; Makrynikola V; Bradstock K
Prog Clin Biol Res; 1992; 377():41-7. PubMed ID: 1438438
[No Abstract] [Full Text] [Related]
20. Use of a lethally irradiated major histocompatibility complex nonrestricted cytotoxic T-cell line for effective purging of marrows containing lysis-sensitive or -resistant leukemic targets.
Cesano A; Pierson G; Visonneau S; Migliaccio AR; Santoli D
Blood; 1996 Jan; 87(1):393-403. PubMed ID: 8547668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]